Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.
Journal: Nature medicine
Published: April 23, 2026
High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.
Journal: Nature medicine
Published: July 29, 2025
Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy.
Journal: The Journal of clinical investigation
Published: March 28, 2025
A Post-Marketing Surveillance Study of Nusinersen for Spinal Muscular Atrophy in Routine Medical Practice in China: Interim Results.
Journal: Advances in therapy
Published: November 20, 2023
DEVOTE Study Exploring Higher Dose of Nusinersen in Spinal Muscular Atrophy: Study Design and Part A Results.
Journal: Journal of neuromuscular diseases
Published: July 02, 2023
Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor Function.
Journal: Journal of clinical medicine
Published: June 13, 2023
Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study.
Journal: Muscle & nerve
Published: August 09, 2022
Matching design for augmenting the control arm of a randomized controlled trial using real-world data.
Journal: Journal of biopharmaceutical statistics
Published: January 31, 2022
Scientific rationale for a higher dose of nusinersen.
Journal: Annals of clinical and translational neurology
Published: December 07, 2021
Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study.
Journal: The Lancet. Child & adolescent health
Published: January 18, 2021
An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.
Journal: CNS drugs
Published: August 18, 2019
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.
Journal: Neuromuscular disorders : NMD
Published: February 26, 2019
Last Updated: 09/26/2026